Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program.
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P). Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act.
To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program.
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SIGHT SCIENCES via THE MCMANUS GROUP
2025 · third_quarter · Q3
Issues related to modernizing payment policy for comprehensive minimally invasive glaucoma surgery procedures.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2025 · third_quarter · Q3
Source: Senate LDA
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION |
| 11 |
| 2023–2025 |
| LARGE UROLOGY GROUP PRACTICE ASSOCIATION | 9 | 2023–2025 |
| ORCHARD THERAPEUTICS NORTH AMERICA | 9 | 2022–2024 |
| INVIVYD (FORMERLY KNOWN AS ADAGIO THERAPEUTICS)) | 8 | 2022–2024 |
| ALNYLAM PHARMACEUTICALS | 7 | 2023–2025 |
| AMERICAN OCCUPATIONAL THERAPY ASSOCIATION | 7 | 2024–2025 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | 2024–2025 |
| DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. | 6 | 2023–2024 |
| AMGEN | 5 | 2024–2025 |
| AVADEL PHARMACEUTICALS | 4 | 2023–2024 |
| FULCRUM THERAPEUTICS | 4 | 2025 |
| PTC THERAPEUTICS, INC. | 4 | 2023 |
| ALKERMES, INC. | 3 | 2023 |
| ROCHE DIAGNOSTICS | 3 | 2024–2025 |
| SIGHT SCIENCES | 2 | 2025 |
| HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) | 1 | 2023 |
| VIVEX BIOLOGICS | 1 | 2024 |
Issues related to physician payment under the Medicare physician fee schedule. Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. Issues related to the supervision requirements for physician and occupational therapy assistants for covered outpatient services under Medicare.
To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program.
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to physician payment under the Medicare physician fee schedule. Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. Issues related to the supervision requirements for physician and occupational therapy assistants for covered outpatient services under Medicare.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Client: FULCRUM THERAPEUTICS · Firm: THE MCMANUS GROUP
Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Client: FULCRUM THERAPEUTICS · Firm: THE MCMANUS GROUP
Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Client: FULCRUM THERAPEUTICS · Firm: THE MCMANUS GROUP
Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.
Medicare Home Health Accessibility Act
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P). Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act.
Medicare Home Health Accessibility Act
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to physician payment under the Medicare physician fee schedule. Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. Issues related to the supervision requirements for physician and occupational therapy assistants for covered outpatient services under Medicare.
Medicare Home Health Accessibility Act
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to physician payment under the Medicare physician fee schedule. Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. Issues related to the supervision requirements for physician and occupational therapy assistants for covered outpatient services under Medicare.
Seniors’ Access to Critical Medications Act of 2025
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 879 - Medicare Patient Access and Practice Stabilization Act. Issues related to physician reimbursement for Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Seniors’ Access to Critical Medications Act of 2025
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 879 - Medicare Patient Access and Practice Stabilization Act. Issues related to physician reimbursement for Part B drugs.
Seniors’ Access to Critical Medications Act of 2025
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. Issues related to physician reimbursement for Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P).
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary and commercially insured patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act Issues related to physician reimbursement under the Medicare physician fee schedule.
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act Issues related to physician reimbursement under the Medicare physician fee schedule.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 879 - Medicare Patient Access and Practice Stabilization Act. Issues related to physician reimbursement for Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Protecting Patient Access to Cancer and Complex Therapies Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. Issues related to physician reimbursement for Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P).
Infertility Treatment Affordability Act of 2025
Client: EMD SERONO, INC. · Firm: THE MCMANUS GROUP
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to IVF treatments, including the Infertility Treatment Affordability Act (H.R. 4639).
No Surprises Act Enforcement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act, including the No Surprises Act Enforcement Act (H.R. 4710/S. 2420).
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ROCHE DIAGNOSTICS · Firm: THE MCMANUS GROUP
Access to and reimbursement of medical devices, specifically diagnostics, in the Medicare program. Issues related to Medicare reimbursement for clinical laboratory services under the Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) of 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 879 - Medicare Patient Access and Practice Stabilization Act. Issues related to physician reimbursement for Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Medicare Patient Access and Practice Stabilization Act of 2025
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 879 - Medicare Patient Access and Practice Stabilization Act. Issues related to physician reimbursement for Part B drugs.
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: ROCHE DIAGNOSTICS · Firm: THE MCMANUS GROUP
Access to and reimbursement of medical devices, specifically diagnostics, in the Medicare program. Issues related to Medicare reimbursement for clinical laboratory services under the Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) of 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: ROCHE DIAGNOSTICS · Firm: THE MCMANUS GROUP
Access to and reimbursement of medical devices, specifically diagnostics, in the Medicare program. Issues related to Medicare reimbursement for clinical laboratory services under the Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) of 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Medicare Beneficiary Co-Pay Fairness Act
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Medicare Beneficiary Co-Pay Fairness Act
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Medicare Beneficiary Co-Pay Fairness Act
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary and commercially insured patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
No Surprises Act Enforcement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act, including the No Surprises Act Enforcement Act (H.R. 4710/S. 2420).
A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Client: FULCRUM THERAPEUTICS · Firm: THE MCMANUS GROUP
Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Client: FULCRUM THERAPEUTICS · Firm: THE MCMANUS GROUP
Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Client: FULCRUM THERAPEUTICS · Firm: THE MCMANUS GROUP
Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.
Support for S. 839, EPIC Act and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Policies related to the Most Favored Nation Drug Pricing Model
Methane Waste Prevention Act of 2021
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Support for S. 839, EPIC Act and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Policies related to the Most Favored Nation Drug Pricing Model.
Methane Waste Prevention Act of 2021
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Methane Waste Prevention Act of 2021
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - H.R. 1492
Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022
Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022
Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Foster Care Stabilization Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P).
Foster Care Stabilization Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
To amend the Child Abuse Prevention and Treatment Act with respect to infants born with and identified as being affected by substance use or withdrawal symptoms, Neonatal Abstinence Syndrome, or Fetal Alcohol Spectrum Disorder, and for other purposes.
Client: INFUSION PROVIDERS ALLIANCE · Firm: THE MCMANUS GROUP
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
To amend the Child Abuse Prevention and Treatment Act with respect to infants born with and identified as being affected by substance use or withdrawal symptoms, Neonatal Abstinence Syndrome, or Fetal Alcohol Spectrum Disorder, and for other purposes.
Client: INFUSION PROVIDERS ALLIANCE · Firm: THE MCMANUS GROUP
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs.
College Transparency Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Support for S. 839, EPIC Act and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Policies related to the Most Favored Nation Drug Pricing Model.
Support for S. 839, EPIC Act and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Policies related to the Most Favored Nation Drug Pricing Model
College Transparency Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Issues related to Artificial Intelligence approval in Medical Devices H.R.1557 - BID Act of 2023 as part of H.R. 1/S. 947- Lower Energy Costs Act
Issues related to Artificial Intelligence approval in Medical Devices H.R.1557 - BID Act of 2023 as part of H.R. 1/S. 947- Lower Energy Costs Act H.R.8818 - American privacy Rights Act of 2024
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: AMGEN · Firm: THE MCMANUS GROUP
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program and H.R.8574 - To amend the Public Health Service Act to reform the 340B drug pricing program, and for other purposes. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Access and reimbursement of Part B Drugs in Medicare. Extension of certain telehealth flexibilities included in H.R. 10545 the American Relief Act, 2025 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Issues related to physician payment included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407/S.2085 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; and H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: EMD SERONO, INC. · Firm: THE MCMANUS GROUP
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Issues related to IVF treatments.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, and S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to reimbursement of medical devices in Medicare program including in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. H.R.5547/S. 476- Maintaining Investments in New Innovation Act S.2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023 S.3131 - ORPHAN Cures Act, H.R.5539 - Optimizing Research Progress Hope and New Cures Act
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. H.R. 4878, the EMPOWER Act, S.2459 - Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act H.R.7148 - Medicare Home Health Accessibility Act Extension of certain telehealth flexibilities in H.R. 10545, the American Relief Act, 2025 Issues related to physician payment included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
American Relief Act, 2025
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Access and reimbursement of Part B Drugs in Medicare. Extension of certain telehealth flexibilities included in H.R. 10545 the American Relief Act, 2025 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Issues related to physician payment included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act
American Relief Act, 2025
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. H.R. 4878, the EMPOWER Act, S.2459 - Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act H.R.7148 - Medicare Home Health Accessibility Act Extension of certain telehealth flexibilities in H.R. 10545, the American Relief Act, 2025 Issues related to physician payment included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Issues related to Artificial Intelligence approval in Medical Devices H.R.1557 - BID Act of 2023 as part of H.R. 1/S. 947- Lower Energy Costs Act H.R.8818 - American privacy Rights Act of 2024
Issues related to Artificial Intelligence approval in Medical Devices H.R.1557 - BID Act of 2023 as part of H.R. 1/S. 947- Lower Energy Costs Act
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ROCHE DIAGNOSTICS · Firm: THE MCMANUS GROUP
Issues related to H.R.1835 - Saving Access to Laboratory Services Act H.R. 1691- Ensuring Patient Access to Critical Breakthrough Products Act
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, and S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to reimbursement of medical devices in Medicare program including in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, and S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Saving Access to Laboratory Services Act
Client: ROCHE DIAGNOSTICS · Firm: THE MCMANUS GROUP
Issues related to H.R.1835 - Saving Access to Laboratory Services Act H.R. 1691- Ensuring Patient Access to Critical Breakthrough Products Act
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407/S.2085 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; and H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Strengthening Medicare for Patients and Providers Act
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Continued access to occupational therapy services including in the Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act. Continued expansion of telehealth services in H.R. 3875, S.2880 - Expanded Telehealth Access Act and the Telehealth Modernization Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act and S. 2016 - CONNECT for Health Act of 2023. Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. H.R. 4878, the EMPOWER Act, S.2459 - Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act H.R.7148 - Medicare Home Health Accessibility Act H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act
Strengthening Medicare for Patients and Providers Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in H.R. 3875/S.3967 - Expanded Telehealth Access Act and H.R. 7623 - Telehealth Modernization Act of 2024. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. H.R.4822 - Health Care Price Transparency Act of 2023 Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act
Strengthening Medicare for Patients and Providers Act
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. H.R. 4878, the EMPOWER Act, S.2459 - Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act H.R.7148 - Medicare Home Health Accessibility Act Extension of certain telehealth flexibilities in H.R. 10545, the American Relief Act, 2025 Issues related to physician payment included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Strengthening Medicare for Patients and Providers Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3875 - Expanded Telehealth Access Act and H.R. 7623 - Telehealth Modernization Act of 2024. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Issues related to Artificial Intelligences approval in Medical Devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FULCRUM THERAPEUTICS via THE MCMANUS GROUP
2025 · third_quarter · Q3
Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS via THE MCMANUS GROUP
2025 · third_quarter · Q3
Access to and reimbursement of medical devices, specifically diagnostics, in the Medicare program. Issues related to Medicare reimbursement for clinical laboratory services under the Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) of 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2025 · third_quarter · Q3
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2025 · third_quarter · Q3
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act Issues related to physician reimbursement under the Medicare physician fee schedule.
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act, including the No Surprises Act Enforcement Act (H.R. 4710/S. 2420).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2025 · third_quarter · Q3
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2025 · third_quarter · Q3
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. Issues related to physician reimbursement for Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P).
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2025 · third_quarter · Q3
Advocating for access to and reimbursement for biosimilars.
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2025 · third_quarter · Q3
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2025 · third_quarter · Q3
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Issues related to site neutrality. Issues related to provider and insurer payment transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2025 · third_quarter · Q3
Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P). Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2025 · third_quarter · 3T
Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2025 · third_quarter · Q3
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to IVF treatments, including the Infertility Treatment Affordability Act (H.R. 4639).
Support for S. 839, EPIC Act and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Policies related to the Most Favored Nation Drug Pricing Model.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIGHT SCIENCES via THE MCMANUS GROUP
2025 · second_quarter · Q2
Issues related to modernizing payment policy for comprehensive minimally invasive glaucoma surgery procedures
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2025 · second_quarter · Q2
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to IVF treatments.
Support for S. 839, EPIC Act and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Policies related to the Most Favored Nation Drug Pricing Model
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2025 · second_quarter · Q2
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2025 · second_quarter · Q2
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2025 · second_quarter · Q2
Issues related to physician payment under the Medicare physician fee schedule. Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. Issues related to the supervision requirements for physician and occupational therapy assistants for covered outpatient services under Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2025 · second_quarter · Q2
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2025 · second_quarter · Q2
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Advocating for access to and reimbursement for biosimilars. Issues related to patient access to infusion products for asthma and allergies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2025 · second_quarter · Q2
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 879 - Medicare Patient Access and Practice Stabilization Act. Issues related to physician reimbursement for Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2025 · second_quarter · Q2
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act Issues related to physician reimbursement under the Medicare physician fee schedule.
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS via THE MCMANUS GROUP
2025 · second_quarter · Q2
Access to and reimbursement of medical devices, specifically diagnostics, in the Medicare program. Issues related to Medicare reimbursement for clinical laboratory services under the Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) of 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FULCRUM THERAPEUTICS via THE MCMANUS GROUP
2025 · second_quarter · Q2
Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2025 · second_quarter · Q2
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Issues related to Artificial Intelligences approval in Medical Devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2025 · second_quarter · Q2
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary and commercially insured patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Issues related to site neutrality. Issues related to provider and insurer payment transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2025 · second_quarter · Q2
Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FULCRUM THERAPEUTICS via THE MCMANUS GROUP
2025 · first_quarter · Q1
Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2025 · first_quarter · Q1
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers.
Issues related to Artificial Intelligences approval in Medical Devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2025 · first_quarter · Q1
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - H.R. 1492
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2025 · first_quarter · Q1
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers. Issues related to physician reimbursement under the Medicare physician fee schedule.
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2025 · first_quarter · Q1
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Access to and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2025 · first_quarter · Q1
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 879 - Medicare Patient Access and Practice Stabilization Act. Issues related to physician reimbursement for Part B drugs.
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2025 · first_quarter · Q1
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs.
Advocating for access to and reimbursement for biosimilars. Issues related to patient access to infusion products for asthma and allergies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2025 · first_quarter · Q1
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2025 · first_quarter · Q1
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to IVF treatments.
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2025 · first_quarter · Q1
Advocacy for increase patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary and commercially insured patients to ASCs.
Issues related to site neutrality. Issues related to provider and insurer payment transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2025 · first_quarter · Q1
Issues related to physician payment under the Medicare physician fee schedule. Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. Issues related to the supervision requirements for physician and occupational therapy assistants for covered outpatient services under Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Q1
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2025 · first_quarter · Q1
Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FULCRUM THERAPEUTICS via THE MCMANUS GROUP
2025 · first_quarter · RR
Sickle Cell disease education Orphan Drug Tax Credit Priority review vouchers
ZIMMER BIOMET via THE MCMANUS GROUP
2024 · fourth_quarter · Q4
Issues related to Artificial Intelligence approval in Medical Devices H.R.8818 - American privacy Rights Act of 2024
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, and S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2024 · fourth_quarter · Q4
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. H.R.5547/S. 476- Maintaining Investments in New Innovation Act S.2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023 S.3131 - ORPHAN Cures Act, H.R.5539 - Optimizing Research Progress Hope and New Cures Act
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program and H.R.8574 - To amend the Public Health Service Act to reform the 340B drug pricing program, and for other purposes. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2024 · fourth_quarter · Q4
Implementation of provisions included in Subtitle BB of PL. 116-260 - No Surprises Act
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2024 · fourth_quarter · Q4
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, and S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to reimbursement of medical devices in Medicare program including in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2024 · fourth_quarter · Q4
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Access and reimbursement of Part B Drugs in Medicare. Extension of certain telehealth flexibilities included in H.R. 10545 the American Relief Act, 2025. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Issues related to physician payment in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2024 · fourth_quarter · Q4
Advocating for access to biosimilars.
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act. Issues related to White Bagging. Issues related to virtual supervision of infusion drugs. Issues related to down coding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Extension of certain telehealth flexibilities included in H.R. 10545 the American Relief Act, 2025 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Issues related to physician payment included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2024 · fourth_quarter · Q4
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Issues related to IVF treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2024 · fourth_quarter · Q4
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
Access and reimbursement of Part B Drugs in Medicare. Extension of certain telehealth flexibilities included in H.R. 10545 the American Relief Act, 2025 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Issues related to physician payment included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2024 · fourth_quarter · Q4
Increased patient access and reimbursement to procedures in ambulatory surgical centers including in H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
H.R.5378 - Lower Costs, More Transparency Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2024 · fourth_quarter · Q4
Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. H.R. 4878, the EMPOWER Act, S.2459 - Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act H.R.7148 - Medicare Home Health Accessibility Act Extension of certain telehealth flexibilities in H.R. 10545, the American Relief Act, 2025 Issues related to physician payment included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Q4
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2024 · fourth_quarter · Q4
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407/S.2085 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; and H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2024 · third_quarter · Q3
Issues related to Artificial Intelligence approval in Medical Devices H.R.1557 - BID Act of 2023 as part of H.R. 1/S. 947- Lower Energy Costs Act H.R.8818 - American privacy Rights Act of 2024
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2024 · third_quarter · Q3
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program and H.R.8574 - To amend the Public Health Service Act to reform the 340B drug pricing program, and for other purposes. Issues related to commercial delinking of PBMs in H.R.6283 - DRUG Act, S.1542 - DRUG Act
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R. 5378: Lower Costs, More Transparency Act, S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 H.R. 2666 - Medicaid VBPs for Patients (MVP) Act Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act, H.R. 7623 - Telehealth Modernization Act of 2024 H.R.5547/S. 476- Maintaining Investments in New Innovation Act S.2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023 S.3131 - ORPHAN Cures Act, H.R.5539 - Optimizing Research Progress Hope and New Cures Act
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2024 · third_quarter · Q3
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Implementation of provisions included in Subtitle BB of PL. 116-260 - No Surprises Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2024 · third_quarter · Q3
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2024 · third_quarter · Q3
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in H.R. 3875/S.3967 - Expanded Telehealth Access Act and H.R. 7623 - Telehealth Modernization Act of 2024. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. H.R.4822 - Health Care Price Transparency Act of 2023 Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2024 · third_quarter · Q3
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act. Issues related to White Bagging. Issues related to virtual supervision of infusion drugs. Issues related to down coding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Advocating for access to biosimilars.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2024 · third_quarter · Q3
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2024 · third_quarter · Q3
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act, S. 2973 - The Modernizing and Ensuring PBM Accountability (MEPA) Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act, H.R.7623 - Telehealth Modernization Act H.R. 5378: Lower Costs, More Transparency Act, S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to commercial delinking of PBMs in H.R.6283 - DRUG Act, S.1542 - DRUG Act Issues related to IVF treatments.
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2024 · third_quarter · Q3
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3875 - Expanded Telehealth Access Act and H.R. 7623 - Telehealth Modernization Act of 2024. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2024 · third_quarter · Q3
Increased patient access and reimbursement to procedures in ambulatory surgical centers including in H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
H.R. 5378: Lower Costs, More Transparency Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2024 · third_quarter · Q3
Continued access to occupational therapy services including in the Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act. Continued expansion of telehealth services in H.R. 3875, S.2880 - Expanded Telehealth Access Act H.R. 7623 - the Telehealth Modernization Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act and S. 2016 - CONNECT for Health Act of 2023. Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. H.R. 4878, the EMPOWER Act, S.2459 - Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act H.R.7148 - Medicare Home Health Accessibility Act H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Q3
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to commercial delinking of PBMs in H.R. 6283/S.1542
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act H.R. 5378: Lower Costs More Transparency Act S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, and S.1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act, H.R. 7623 - Telehealth Modernization Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS via THE MCMANUS GROUP
2024 · third_quarter · RR
Issues related to H.R.1835 - Saving Access to Laboratory Services Act H.R. 1691- Ensuring Patient Access to Critical Breakthrough Products Act
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2024 · second_quarter · Q2
Issues related to the CHANGE Healthcare Cyber-Attack Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Advocating for access to biosimilars. S. 652/HR 2630, Safe Step Act. S. 1375/HR 830, HELP Copays Act. Access to Alzheimer's Disease therapies.
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act. Issues related to White Bagging. Issues related to virtual supervision of infusion drugs. Issues related to down coding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2024 · second_quarter · Q2
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Q2
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to commercial delinking of PBMs in H.R. 6283/S.1542
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act H.R. 5378: Lower Costs More Transparency Act S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, and S.1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2024 · second_quarter · Q2
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2024 · second_quarter · Q2
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R. 5378: Lower Costs, More Transparency Act, S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 H.R. 2666 - Medicaid VBPs for Patients (MVP) Act Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act H.R.5547/S. 476- MINI Act S.2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023 S.3131 - ORPHAN Cures Act, H.R.5539 - Optimizing Research Progress Hope and New Cures Act
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program and H.R.8574 - To amend the Public Health Service Act to reform the 340B drug pricing program, and for other purposes. Issues related to commercial delinking of PBMs in H.R.6283 - DRUG Act, S.1542 - DRUG Act H.R.7085 - BIOSECURE Act
ZIMMER BIOMET via THE MCMANUS GROUP
2024 · second_quarter · Q2
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Issues related to Artificial Intelligence approval in Medical Devices H.R.1557 - BID Act of 2023 as part of H.R. 1/S. 947- Lower Energy Costs Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2024 · second_quarter · Q2
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2024 · second_quarter · Q2
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Implementation of provisions included in Subtitle BB of PL. 116-260 - No Surprises Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2024 · second_quarter · Q2
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in H.R. 3857/S.3967 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. H.R.4822 - Health Care Price Transparency Act of 2023 Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act
EMD SERONO, INC. via THE MCMANUS GROUP
2024 · second_quarter · Q2
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to commercial delinking of PBMs in H.R.6283 - DRUG Act, S.1542 - DRUG Act H.R.7085 - BIOSECURE Act Issues related to IVF treatments.
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023.
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2024 · second_quarter · Q2
Continued access to occupational therapy services including in the Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act. Continued expansion of telehealth services in H.R. 3875, S.2880 - Expanded Telehealth Access Act and the Telehealth Modernization Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act and S. 2016 - CONNECT for Health Act of 2023. Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. H.R. 4878, the EMPOWER Act, S.2459 - Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act H.R.7148 - Medicare Home Health Accessibility Act H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2024 · second_quarter · Q2
Increased patient access and reimbursement to procedures in ambulatory surgical centers including in H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
H.R. 5378: Lower Costs, More Transparency Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2024 · first_quarter · Q1
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Issues related to Artificial Intelligence approval in Medical Devices
Issues related to research and development tax amortization in H.R. 2673 - American Innovation and R&D competitiveness Act of 2023 H.R.7024 - Tax Relief for American Families and Workers Act of 2024
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2024 · first_quarter · Q1
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R. 5378: Lower Costs, More Transparency Act, S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 H.R. 2666 - Medicaid VBPs for Patients (MVP) Act Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to commercial delinking of PBMs in H.R.6283 - DRUG Act, S.1542 - DRUG Act H.R.7085 - BIOSECURE Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via THE MCMANUS GROUP
2024 · first_quarter · 1T
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2024 · first_quarter · Q1
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Implementation of provisions included in Subtitle BB of PL. 116-260 - No Surprises Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2024 · first_quarter · Q1
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2024 · first_quarter · Q1
H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in H.R. 3857/S.3967 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. H.R.4822 - Health Care Price Transparency Act of 2023 H.R. 3284, the Providers and Payers COMPETE Act. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
INVIVYD (FORMERLY KNOWN AS ADAGIO THERAPEUTICS)) via THE MCMANUS GROUP
2024 · first_quarter · 1T
Education and awareness related to COVID-19 therapeutics. Issues related to H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act and S.2333 - Pandemic and All-Hazards Preparedness and Response Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2024 · first_quarter · Q1
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act. Issues related to White Bagging.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
GRAIL, INC. via THE MCMANUS GROUP
2024 · first_quarter · Q1
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2024 · first_quarter · Q1
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023. H.R.7024 - Tax Relief for American Families and Workers Act of 2024
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to commercial delinking of PBMs in H.R.6283 - DRUG Act, S.1542 - DRUG Act H.R.7085 - BIOSECURE Act Issues related to IVF treatments.
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2024 · first_quarter · Q1
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R. 3284, the Providers and Payers COMPETE Act. H.R.6683 - Preserving Seniors Access to Physicians Act of 2023
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
AVADEL PHARMACEUTICALS via THE MCMANUS GROUP
2024 · first_quarter · 1T
Increased access to narcoleptic medication (S.574/H.R.4692 - Increasing Prescription Drug Competition Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2024 · first_quarter · Q1
H.R. 5378: Lower Costs, More Transparency Act. S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S.3548 - Health Care Prices Revealed and Information to Consumers Explained Transparency Act
Increased patient access and reimbursement to procedures in ambulatory surgical centers including in H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023. Site neutrality provisions including in H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. H.R.5378 - Lower Costs, More Transparency Act S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2024 · first_quarter · Q1
Continued access to occupational therapy services including in the Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act. Continued expansion of telehealth services in H.R. 3875, S.2880 - Expanded Telehealth Access Act and the Telehealth Modernization Act, H.R.4189/S. 2016 - CONNECT for Health Act of 2023. Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. H.R. 4878, the EMPOWER Act, S.2459 - Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act H.R.7148 - Medicare Home Health Accessibility Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Q1
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S.1375/H.R.830 - HELP Copays Act. Issues related to commercial delinking of PBMs in H.R. 6283/S.1542 Support for H.Res.709 - Supporting the designation of September 2023 as "National Cholesterol Education Month", and September 30, 2023, as LDL-C Awareness Day.
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act H.R. 5378: Lower Costs More Transparency Act S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, and S.1967 - PBM Act
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2024 · first_quarter · Q1
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 H.R. 5539, S.3131 - ORPHAN Cures Act Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIVEX BIOLOGICS via THE MCMANUS GROUP
2024 · first_quarter · RR
Issues related to HCT/P legislation (e.g. HR 7188/S. 3733)
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Issues related to PPBM transparency, including, H.R.5378 - Lower Costs, More Transparency Act
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to down coding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Advocating for access to biosimilars. HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act. S. 652/HR 2630, Safe Step Act S. 1375/HR 830, HELP Copays Act Issues related to White Bagging. Access to Alzheimer's Disease therapies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Issues related to research and development tax amortization in H.R. 2673 - American Innovation and R&D competitiveness Act of 2023 S.866 - American Innovation and Jobs Act
Issues related to Ethylene Oxide (EtO) sterilization.
Access and reimbursement of medical devices in Medicare program. Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
PTC THERAPEUTICS INC. via THE MCMANUS GROUP
2023 · fourth_quarter · 4T
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patients (MVP) Act). Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act, S. 2973 - The Modernizing and Ensuring PBM Accountability (MEPA) Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 5378: Lower Costs, More Transparency Act, S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act H.R. 5378: Lower Costs, More Transparency Act, S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE